Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Biomarkers - what for?
- CVD as exemplar
- Lipids: which ones and when?
- Do apolipoproteins add value?
- CVD risk charts
- Biomarker variety
- CRP, statins and CVD
- NT-proBNP
- CVD biomarkers: prediction benchmark higher
- Prediction lessons from CVD biomarker research
- Pathways for finding biomarkers
- Biomarkers in diabetes - pathogenesis insights
- WOSCOPS: 1.CRP 2.LFT's
- CRP and incident diabetes
- Risk factors for disease
- Liver function as a biomarker
- ALT & incident diabetes
- ALT and incident diabetes: meta-analysis
- ALT as a diabetes biomarker
- Fat accumulation in liver - clinical signs?
- Liver fat vs. alcohol
- Liver disease and other causative factors
- Keeping liver fat low
- Fibre intake and diabetes
- Adiponectin as a biomarker
- Biomarker for pathogenesis: summary
- Biomarkers in diabetes - prediction benefits
- BRHS & BWHHS data >60 year old
- Risk prediction scores
- Biomarkers diabetes prediction summary
- Adiposity prediction confusion
- Combined CVD risk / Diabetes screening
- Biomarkers in diabetes
- 29 RCTs DM patients: simple predictors of risk
- Definition of abnormality
- Biomarkers - complications / treatment guidance?
- Diabetes biomarkers - ready for prime time?
Topics Covered
- For what reason do we need further biomarker research in diabetes?
- Prediction of diabetes
- Prediction of complications
- Personalized therapy
- Biomarkers role in understanding the pathophysiology of diabetes
- Biomarkers and genetics
Links
Series:
Categories:
- Biochemistry
- Cell Biology
- Diseases, Disorders & Treatments
- Metabolism & Nutrition
- Pharmaceutical Sciences
Therapeutic Areas:
Talk Citation
Sattar, N. (2013, June 24). Diabetes biomarkers [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2019, from https://hstalks.com/bs/2572/.Publication History
Financial Disclosures
- Prof. Naveed Sattar has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Diabetes biomarkers
Published on June 24, 2013
32 min
Transcript
0:00
Hello, my
name is Naveed Sattar.
I am professor of metabolic medicine
at the University of Glasglow,
and I am going to give you an
overview of diabetes biomarkers.
0:12
So biomarkers, what are they?
And what are they for?
Biomarkers are really any measure,
whether it's biological material
or even a clinical
characteristic which
gives you insight
into either disease,
pathogenesis, prediction of
complications or progression
of follow up. Or it can
actually give you an insight
into the response of an
individual to a particular therapy
or intervention.
So biomarkers can range from simple
things such as age, social class,
but of course, most people
understand the term biomarkers
in terms of some blood measure
or some biochemical parameter,
for example, cholesterol or glucose.
0:52
If we take cardiovascular disease
as an example of how they have used
biomarkers, well, we
are now at a point
where we know that age, blood
pressure, smoking, gender, lipids,
and the presence of diabetes gives
insight into cardiovascular risk.
And from this, we have developed
cardiovascular risk scores,
ranging from the original
Framingham risk scores
through to the risk score in Europe,
as well as more sophisticated risk
scores which have added other
potential parameters which we
will discuss in the
next couple of slides.
There is big-scale epidemiology
on these routine biomarkers
in cardiovascular disease
in terms of prediction.
And some of the lessons we have
learned from cardiovascular disease
in terms of predicting disease
are relevant to diabetes research.